FIELD: chemistry.SUBSTANCE: invention relates to a compound of general formula (I), N-oxides thereof on a pyridine ring and pharmaceutically acceptable salts thereof: (I), where: R1 and R2 are different or identical and are independently selected from the group consisting of: linear (C1-C6)-alkyl optionally substituted with one substituent selected from (C3-C7)-cycloalkyl； (C1-C6)-haloalkyl； (C3-C7)-cycloalkyl； R3 is H or represents one or two substituents independently selected from halogen atoms； Z represents a group (CH2)m, where m is 0； A is a phenyl ring optionally substituted by one substituent R4, which is selected from the group consisting of: linear (C1-C6)-alkyl substituted with one morpholinyl； branched (C1-C6)-alkyl optionally substituted by one (C3-C7)-cycloalkyl； (C1-C6)-haloalkyl； (C1-C6)-alkylthio； a halogen atom； and OR7, where R7 is selected from the group consisting of H； (C1-C10)-alkyl optionally substituted by a radical selected from (C3-C7)-cycloalkyl, morpholinyl, phenyl and pyridinyl； and (C1-C10)-alkyl substituted with one OH group； (C1-C6)-haloalkyl； (C3-C7)-cycloalkyl； W is selected from the group consisting of: -NR9SO2R10, -CH2NR13SO2R14, -SO2NR15R16, -NHSO2R17, -OSO2R18, -NHCOR26, where R9, R10, R13, R14, R15, R16, R17, R18, R26 are defined in the claims. Invention also relates to a pharmaceutical composition having PDE4 inhibitory activity based on compounds of formula (I), to an apparatus comprising the composition.EFFECT: technical result is obtaining novel compounds and pharmaceutical compositions based thereon, that can be used in medicine for the treatment of an allergic disease or respiratory diseases such as atopic dermatitis, urticaria, allergic rhinitis, asthma and COPD.14 cl, 22 tbl, 37 exИзобретение относится к соединению общей формулы (I), его N-оксидам по пиридиновому кольцу и их фармацевтически приемлемым солям:, где: R1 и R2 являются разными или одинаковыми и независимо выбраны из группы, состоящей из: линейного (С1-С6)-
